2024-513091-17-00
Active, not recruiting
Phase 3
Low-dose AtropIne for Myopia control in children
Medical Center - University Of Freiburg16 sites in 1 country300 target enrollmentStarted: October 24, 2024Last updated:
Overview
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Medical Center - University Of Freiburg
- Enrollment
- 300
- Locations
- 16
- Primary Endpoint
- Change of cycloplegic refraction/year [D/year] after 1 year of treatment.
Overview
Brief Summary
The primary objective is to demonstrate superiority of low-dose atropine 0.02% eye drops compared to placebo for myopia control in children of Caucasian origin, measured as change of cycloplegic refraction/year [diopter per year (D/year)] after one year of treatment.
Eligibility Criteria
- Ages
- 0 years to 17 years (0-17 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female patients aged 8 to 12 years (up to the day before the 13th birthday)
- •Myopia of -1 D to -6 D with reported or documented annual progression ≥ 0.5 D of myopia
- •Written informed consent obtained from patient (if applicable) and parents or legal guardians according to international guidelines and local laws
- •Ability to understand the nature of the trial and the trial related procedures and to comply with them
Exclusion Criteria
- •Asian or African origin
- •Any known systemic metabolic disease or chromosomal anomaly
- •Previous use of any kind of contact lenses
- •Previous use of atropine eye drops
- •Known hypersensitivity to the active substances or any of the excipients
- •Participation in any other interventional clinical trial within the last 30 days before the start of this trial
- •Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed
- •Contraindications according to the Summary of Product Characteristics (SmPC): Increased intraocular pressure (primary forms of glaucoma or narrow angle glaucoma), chronic rhinitis sicca
- •Caution and pediatric counselling shall be assured if any of the following conditions are present according to the Summary of Product Characteristics (SmPC): Cardiac insufficiency, arrhythmia, coronary stenosis, hyperthyroidism, stomach or bowel stenosis, bowel paralysis, megacolon, muscle weakness, lung edema, hypersensitivity to atropine, spastic paralysis
- •Parents or children with poor understanding of the German language
Outcomes
Primary Outcomes
Change of cycloplegic refraction/year [D/year] after 1 year of treatment.
Change of cycloplegic refraction/year [D/year] after 1 year of treatment.
Secondary Outcomes
- Axial eye length change/year [mm/year] after 1 year.
- Categorized rate of change in refraction and eye length after 1 year.
Investigators
Coordinating Investigator
Scientific
Medical Center - University Of Freiburg
Study Sites (16)
Loading locations...
Similar Trials
Recruiting
Phase 3
ow-dose Atropine for Myopia control in childreMyopia in childrenDRKS00023337niversitätsklinikum Freiburg300
Active, not recruiting
Phase 1
ow-dose AtropIne for Myopia control in childreEUCTR2020-001575-33-DEniversitätsklinikum Freiburg300
Active, not recruiting
Phase 2
Low-dose Atropine for Myopia Control in ChildrenMyopia, ProgressiveNCT03865160University Eye Hospital, Freiburg302
Recruiting
Phase 4
Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling MyopiaMyopiaNCT05448989Shanghai Eye Disease Prevention and Treatment Center192
Recruiting
Not Applicable
Effect of low dose Atropine Eye drops in children with Short-Sightedness.CTRI/2019/01/017010RASHMI K104